"Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches"

Sponsor
Ankara City Hospital Bilkent (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06061588
Collaborator
(none)
100
1
2
13
7.7

Study Details

Study Description

Brief Summary

The primary objective of this research is to investigate the effects of virtual reality technology on the treatment of migraine-type headaches and assess how this technology may impact the severity, frequency, and duration of headaches.

Condition or Disease Intervention/Treatment Phase
  • Device: Virtual Reality
N/A

Detailed Description

This is a randomized observational study with the primary objective of investigating the effects of virtual reality technology on the treatment of migraine-type headaches and assessing how this technology can potentially influence the severity, frequency, and duration of headaches. Additionally, the study aims to analyze the impact of virtual reality technology on the neurological and psychological components of headaches, evaluate potential improvements in the quality of life for migraine patients undergoing virtual reality therapy, monitor the long-term effects of virtual reality in migraine treatment, and assess its sustainability. The study is divided into two arms, labeled as Arm 1 and Arm 2, with randomization being carried out by the principal investigator. All patients consenting to participate in the study will receive a standard treatment of 150 cc normal saline containing arveles (50 mg dexketoprofen), and no patient will be left untreated. One group will receive only the standard treatment (control group), while the other group will receive both the standard treatment and, in addition, virtual reality therapy consisting of a virtual environment simulating moonlight by the dark seaside or a campfire ambiance with classical music (calm, slow, and soothing) using virtual reality goggles.

Prior to medication administration and at 15, 30, 60, and 120 minutes, patients' VAS scores will be recorded. Adult patients diagnosed with migraines who have agreed to participate in the study will be included. Patients will be eligible to participate in the study if they meet specific inclusion criteria. The severity of pain in patients diagnosed with migraines and the effectiveness of treatments used for migraine attacks will constitute the dependent variables of the study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
The study is planned to be conducted at two centers. Patients visiting one hospital will receive standard treatment, while patients visiting the other hospital will receive standard treatment plus VR goggles as part of their therapy. The group receiving standard treatment will constitute the case group, while the other group will form the control group.The study is planned to be conducted at two centers. Patients visiting one hospital will receive standard treatment, while patients visiting the other hospital will receive standard treatment plus VR goggles as part of their therapy. The group receiving standard treatment will constitute the case group, while the other group will form the control group.
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches: Randomized Observational Study
Anticipated Study Start Date :
Oct 31, 2023
Anticipated Primary Completion Date :
Oct 31, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
No Intervention: The case group

Included in the case group, patients diagnosed with migraine and experiencing headache will receive standard treatment, consisting of 50 mg of dexketoprofen within 150 cc of normal saline.

Experimental: The control group

The control group, in addition to standard treatment, will be treated with virtual reality therapy using VR goggles, which will create a virtual environment simulating moonlight by the dark seaside or a campfire ambiance with classical music (calm, slow, and soothing).

Device: Virtual Reality
The use of virtual reality as an adjunct to routine treatment.

Outcome Measures

Primary Outcome Measures

  1. Visual Analogue Scale [15. -30.-60.-120. minutes]

    The change in patients' pain conditions with treatment. The pain is determined using a 100 mm scale. Patients are instructed to mark the level of pain they experience, with 0 mm indicating no pain and 100 mm indicating the presence of maximum pain.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years of age or older

  • Under the age of 60

  • Willing to participate in the study

  • Previously diagnosed with migraine

  • Marking a VAS score of 50 or higher

  • Not considered for any additional preliminary diagnosis

  • No known adverse history to the active ingredient of the medication to be used

  • Conscious

  • Cooperatively oriented

Exclusion Criteria:
  • Under 18 years of age or over 60 years of age

  • Not willing to participate in the study

  • Displaying vital signs outside of normal limits

  • With a known history of adverse reactions to NSAIDs

  • Unable to determine the severity of pain on the VAS

  • Scoring 50 mm or lower on the VAS

  • Pregnant individuals

  • Individuals with advanced systemic illness

  • Those with malignancies

  • Patients with chronic liver and kidney disease

  • Using sedative and analgesic neuro-psychiatric drugs

  • With a history of psychological and neurological diseases

  • Having taken analgesics within 8 hours prior to examination

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ankara City Hospital Ankara Turkey 06800

Sponsors and Collaborators

  • Ankara City Hospital Bilkent

Investigators

  • Principal Investigator: SAFA DÖNMEZ, M.D., Ankara Bilkent City Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Safa Dönmez, M.D., Ankara City Hospital Bilkent
ClinicalTrials.gov Identifier:
NCT06061588
Other Study ID Numbers:
  • Virtual Reality in Migraine
First Posted:
Sep 29, 2023
Last Update Posted:
Oct 2, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 2, 2023